Bristol-Myers Squibb Co. has announced some executive moves within its senior management team.


Bristol-Myers Squibb, senior management team, executive changes, Giovanni Caforio, U.S. Pharmaceuticals, president, Lamberto Andreotti, Charles Bancroft, Beatrice Cazala, Anthony Hooper, pharmaceutical company


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Senior management changes at Bristol-Myers Squibb

October 19th, 2011

NEW YORK – Bristol-Myers Squibb Co. has announced some executive moves within its senior management team.

The company said Wednesday that Giovanni Caforio has been promoted to president of U.S. Pharmaceuticals. He previously was senior vice president of oncology and immunology global commercialization.

In the new role, Caforio will report to Lamberto Andreotti, chief executive officer, and will become a member of the company's senior management team.

Meanwhile, Charles Bancroft and Beatrice Cazala have been appointed as executive vice presidents.

Bristol-Myers Squibb said Bancroft will add to his role of chief financial officer operational responsibility for the pharmaceutical business in Latin America, Middle East, Africa, Canada, Japan and several other countries in the Pacific Rim. Cazala will add responsibility for global policy to her role leading global commercialization for Europe and emerging markets. Both executives will continue to report to Andreotti and serve on the senior management team.

In addition, the pharmaceutical company said that Anthony Hooper, senior vice president of commercial operations and president of U.S., Japan and intercontinental, has decided to leave the company.

"I am excited to expand the roles of Giovanni, Charlie and Beatrice," Andreotti said in a statement, "and look forward to working with these three senior leaders and the rest of my management team to continue to successfully execute our biopharma strategy."

Advertisement